Bristol-Myers Squibb Company

Bristol-Myers Squibb is a global biopharmaceutical company with a mature oncology franchise (Opdivo, Yervoy, Reblozyl), cardiology (Eliquis with Pfizer), and a pipeline that has to fill the pending patent cliff. The current setup is a defensive quality-value trade at a real multiple discount.

• The valuation is the whole story: 16x TTM earnings and 2.4x sales for a business with a 14% ROIC, 69% gross margin, 26% operating margin, and 10% free-cash-flow yield — priced as a slow-growth pharma with pipeline risk, not as the compounder the FCF economics actually support.
• The dividend is the anchor: at a 4.3% yield with clean coverage from operating cash flow, BMY is a legitimate defensive-yield holding — the specific value setup the crowd is buying alongside PFE, NVO, MRK, and Sanofi as the AI-tech-and-momentum trade absorbs most of the market's attention.
• Fundamentals are stable-but-modest: revenue grew 3% year-over-year last quarter to $11.49B at a 70% gross margin, and last EPS beat by 11% — the underlying operating results are fine, though the growth rate is exactly what makes the multiple compress on any negative headline.
• The Krazati confirmatory colorectal trial stumble is a real specific negative: one late-stage read went the wrong way, and while it's not the whole pipeline, the market has taken it into pricing.

The July 30 earnings is the fulcrum. Firm forward guidance with clean commentary on the post-Krazati pipeline and Opdivo lifecycle trajectory keeps the multiple defensible and can catalyze the healthcare-breakout the crowd flagged at $57.20. A pipeline-timing wobble or a soft Eliquis quarter turns event-ahead into a longer consolidation, but the 10% FCF yield leaves the fundamental floor close.